MacroGenics, Inc. (MGNX)
3.74
+0.19
(+5.35%)
USD |
NASDAQ |
Oct 09, 16:00
3.74
0.00 (0.00%)
After-Hours: 20:00
MacroGenics Net Income (Quarterly) : -69.64M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -69.64M |
| March 31, 2026 | -36.77M |
| December 31, 2025 | -14.16M |
| September 30, 2025 | 16.82M |
| June 30, 2025 | -42.72M |
| March 31, 2025 | -41.04M |
| December 31, 2024 | -15.42M |
| September 30, 2024 | 56.31M |
| June 30, 2024 | -55.66M |
| March 31, 2024 | -52.19M |
| December 31, 2023 | -46.07M |
| September 30, 2023 | 17.55M |
| June 30, 2023 | 57.47M |
| March 31, 2023 | -38.01M |
| December 31, 2022 | 12.80M |
| September 30, 2022 | -24.81M |
| June 30, 2022 | -41.30M |
| March 31, 2022 | -66.44M |
| December 31, 2021 | -58.02M |
| September 30, 2021 | -52.89M |
| June 30, 2021 | -39.94M |
| March 31, 2021 | -51.27M |
| December 31, 2020 | -2.087M |
| September 30, 2020 | -36.04M |
| June 30, 2020 | -46.88M |
| Date | Value |
|---|---|
| March 31, 2020 | -44.72M |
| December 31, 2019 | -30.40M |
| September 30, 2019 | -44.63M |
| June 30, 2019 | -31.77M |
| March 31, 2019 | -45.02M |
| December 31, 2018 | -44.64M |
| September 30, 2018 | -34.03M |
| June 30, 2018 | -43.24M |
| March 31, 2018 | -49.54M |
| December 31, 2017 | 105.73M |
| September 30, 2017 | -47.04M |
| June 30, 2017 | -40.65M |
| March 31, 2017 | -37.66M |
| December 31, 2016 | -34.78M |
| September 30, 2016 | -33.85M |
| June 30, 2016 | 40.46M |
| March 31, 2016 | -30.36M |
| December 31, 2015 | -28.45M |
| September 30, 2015 | -15.44M |
| June 30, 2015 | -21.38M |
| March 31, 2015 | 45.13M |
| December 31, 2014 | -19.02M |
| September 30, 2014 | -3.928M |
| June 30, 2014 | -12.26M |
| March 31, 2014 | -3.108M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -10.50B |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 32.83M |
| Total Expenses (Quarterly) | 102.47M |
| EPS Diluted (Quarterly) | 0.3069 |
| Enterprise Value | 262.98M |
| Gross Profit Margin (Quarterly) | 97.84% |
| Profit Margin (Quarterly) | -212.1% |
| Earnings Yield | -6.16% |
| Normalized Earnings Yield | -6.160 |